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Background: Cathepsin X is a cysteine protease involved in mechanisms of malignant progression. It is secreted
from tumour cells as a proenzyme and may serve to predict the disease status and risk of death for cancer patients.
In a previous, pilot, study on 77 colorectal patients we demonstrated the correlation of higher serum levels with
shorter overall survival.
Methods: 264 patients with colorectal cancer were included in a prospectively accrued multi-centre observational
cohort study with the aim of testing novel biomarkers. Blood samples were collected before preoperative large
bowel endoscopy and total cathepsin X was measured in sera by ELISA. As a control group we selected at random
77 subjects who had no findings at endoscopy and reported no co-morbidity.
Results: The mean level of cathepsin X in cancer patients did not differ from the control levels (23.4 ng/ml ± 6.4
SD vs. 18.8 ng/ml ± 11.4 SD, p > 0.05) and there was no association with age, gender, disease stage, tumour
location or CEA. In univariate analysis no association between cathepsin X levels and overall survival was
demonstrated for the entire set of patients, however, cathepsin X was associated with survival in a group of
patients with local resectable disease (stages I-III) (HR = 1.69, 95% CI: 1.03-2.75, p = 0.03). For this group, multivariate
Cox regression analysis showed an association (HR = 3.13, 95% CI: 1.37-7.18, p = 0.003) between high cathepsin X
levels and shorter overall survival for patients who did not receive chemotherapy, whereas, for patients who
received chemotherapy, there was no association between cathepsin X and survival (HR = 0.51, 95% CI: 0.20-1.33,
p = 0.88).
Conclusions: Association of cathepsin X levels with overall survival was not confirmed for an entire set of 264
colorectal patients, but for patients in stages I-III with local resectable disease. The significant association of cathepsin X
with survival in a group of patients who received no chemotherapy and the absence of this association in the group
who received chemotherapy, suggest the possible predictive value for response to chemotherapy. The results have to
be confirmed in a further prospective study.
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Discovery of molecules associated with colorectal cancer
(CRC) whose levels may provide predictive and prognostic
information, is important in order to improve treatment,
optimize the quality of life and prolong survival of the
patients. Several serum tumour markers are currently
under evaluation, however, carcinoembryonic antigen (CEA)
is the only one in regular clinical use for determining* Correspondence: janko.kos@ffa.uni-lj.si
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unless otherwise stated.prognosis, for surveillance following curative resection and
for monitoring therapy in advanced disease [1-4].
Cysteine cathepsins, a group of lysosomal cysteine
proteases, have been reported as being involved in the
development and progression of cancer. They are used
as targets for developing new antitumour therapies.
Their expression, protein and activity levels [5-7] have also
been associated with prediction of prognosis in various
cancer types, including CRC [8,9]. Cathepsins B and L, in
particular, are the most extensively studied cysteine
cathepsins in colorectal diseases. In colorectal carcinoma
they are generally overexpressed and their ability tod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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related to tumour invasion, migration and metastasis [8,10].
Endogenous inhibitors of cysteine proteases, the cystatins,
insufficiently impair the tumour associated activity of cathep-
sins; their lower levels in tumours, higher enzyme:inhibitor
ratio and lower stability of the complex have been associated
with cancer aggressiveness and patient survival [8,11].
In recent studies the potential of other cathepsins, exhi-
biting more specific functions and localisation than cathep-
sins B and L, have been evaluated. Cathepsin X (Cat X), for
example, is expressed specifically in various cells of the
immune system [12] and regulates important processes
such as proliferation, maturation, migration and adhesion
of immune cells, phagocytosis and signal transduction
[13-15]. Elevated expression of Cat X has also been associ-
ated with the inflammatory processes in inflammatory re-
lated neurodegenerative disorders [16], Helicobacter pylori
infection [17], multiple trauma [18] and tuberculosis [19].
However, there is increasing evidence that Cat X is also
involved in malignant processes. The gene encoding Cat X
is localized in chromosomal region 20q13, which is fre-
quently amplified in several cancer types [20,21]. In lung
tumours, immunohistochemical analysis revealed strong
staining of Cat X in infiltrated immune cells, but very weak
staining in tumour cells [12]. On the other hand, increased
expression of Cat X was found in both tumour and im-
mune cells of prostate [22] and gastric cancer [17] and in
the most aggressive phenotypes of malignant melanoma
[23]. Further, breast cancer transgenic mice with Cat X
deficiency had a prolonged tumour-free period for breast
cancer, unlike wild type mice [24]. Moreover, Cat X defi-
ciency leads to accelerated cell senescence, which is a
powerful tumour suppressing mechanism [25]. Cat X may
also promote tumour processes by mechanisms typical of
immune cells, such as binding and activation of integrin
receptors [15] and modulation of CXCL-12 chemokine
[26] and gamma enolase [16].
Reports evaluating the clinical relevance of Cat X are
less numerous. Wang et al. demonstrated that increased
Cat X mRNA levels in hepatocellular carcinomas correlate
with advanced tumour stage [27]. In a pilot study our group
showed significantly lower levels of active Cat X in sera of
patients with inflammatory breast cancer than with non-
inflammatory breast cancer [28]. However, no significant
correlation with any clinico-pathological parameter could
be demonstrated in epithelial ovarian cancer cyst fluid [29].
On the other hand, higher levels of Cat X (both pro-form
and active mature form) in sera from 77 patients with CRC
correlated significantly to shorter overall survival [30].
In the present study, the aim was to confirm the
results of the pilot study with an extended cohort of
CRC patients and, further, to evaluate the use of serum
levels of total Cat X for selecting patients who could
benefit from chemotherapy.Methods
Patients
The study was approved by the Regional Ethical Committee
of Copenhagen and The Danish Data Protection Agency.
264 subjects diagnosed with primary rectal or colon cancer
and 77 controls were included in a multi-centre observa-
tional cohort study conducted at six Danish hospitals from
October 2003 to December 2005. All gave informed con-
sent to being included in the study. Cancer diagnoses were
verified by histology of resected large bowel specimens.
Patients who did not have the tumour removed for various
reasons were classified according to the available clinical
information and, as a result, exact tumour staging was not
possible in 17 cases. As a control group, we selected sub-
jects at random who had symptoms which could be due to
CRC but exhibited no findings at endoscopy and reported
no co-morbidity (healthy persons). Disease stage was based
on the TNM-stage (International Union Against Cancer
(UICC)). 26 patients with Stages I-III received adjuvant
therapy whereas 33 patients with stage IV received pallia-
tive chemotherapy. It should be emphasized that patients
were not randomized to adjuvant therapy and palliative
chemotherapy but selected as part of the clinical decisions.
Patient characteristics and applied first line therapies are
given in Table 1.
Sampling
Blood samples were collected from healthy persons and
from CRC patients just before preoperative large bowel
endoscopy according to a validated standard operating
procedure. Blood was collected at moderate tourniquet
pressure, in 10 ml serum tubes (Vacutainer® Becton-
Dickinson, Mountain View, CA, USA), and spun for
10 minutes at 3000 g and 4°C within 1 hour of collection.
Samples were immediately stored at −80°C.
Cat X and CEA analysis
Human total Cat X was analysed by ELISA as described
[12,30]. Goat polyclonal antibody (R&D SYSTEMS®,
Minneapolis, USA) and horseradish peroxidase-conjugated
3B10 mouse monoclonal antibody, both recognizing pro-
and mature Cat X, were used. Pro-Cat X, used as a
standard, was prepared and characterized as described
[31]. Serum samples were diluted in a 1:2 ratio with 2%
BSA in 10 mM phosphate buffer (pH 7.2), 150 mM
NaCl and 0.05% Tween® 20 (Sigma-Aldrich Chemie
GmbH, Steinheim, Germany). The range of the calibration
curve for Cat X extended from 1.0 to 32.5 ng/ml (see
Additional file 1: Figure S1). To determine the linearity of
the ELISA, serum samples were serially diluted in 2% BSA
in 10 mM phosphate buffer to levels encompassing the
range of the assay, and their linearity was evaluated by
comparing the measured values with the calibration
values. Dilutions of 4 serum samples showed a linear dose







70.3, 32.7 - 93.3 (median, range) 264 (100.0)
Localisation
Left-sided colon cancer 97 (36.7)
Right-sided colon cancer 63 (23.9)













Subjects, n (%) Subjects, n (%)
5-FU 2 (1.1) 1 (1.4)
5-FU + Isovorin 7 (3.9) 4 (5.8)
Irinotecan + 5-FU 0 (0) 3 (4.3)
Oxaliplatin + 5-FU 7 (3.9) 2 (2.9)
Capecitabine 3 (1.7) 1 (1.4)
Oxaliplatin +
Capecitabine
4 (2.2) 15 (21.7)
Other 1 (0.6) 4 (5.8)
Unknown 2 (1.1) 3 (4.3)
Total 26 (14.6) 33 (47.8)
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range 1:2 to 1:16 (see Additional file 2: Figure S2). To
evaluate recovery rate, recombinant pro-Cat X at different
concentrations was added to serum samples with known
total Cat X concentrations. Recovery levels were deter-
mined by comparing the expected and observed concen-
trations. Recovery levels ranged from 87.0 to 100.6%. Mean
recovery was 92.1%. The plot of expected vs. observed con-
centrations for Cat X ELISA is shown in (see Additional
file 3: Figure S3). The intra-assay coefficient of variance
(CV), determined by measuring 20 control replicates, was
6.5%. Inter-assay precision was derived by evaluating one
high and one low control in duplicates in seven separate
assays and was 7.9%. Detection limit of the assay, defined
as the concentration corresponding to the mean absorb-
ance of 10 replicates of zero standard plus 3 standard
deviations (SDs) was determined to be 0.75 ng/ml.CEA was determined using the Abbott ARCHITECT®
i2000 automated immunoassay system utilising an on-market
two-step dual monoclonal immunoassay (ARCHITECT®
CEA assay). The determination was run at the Abbott
Centre of Excellence research laboratory in Munich,
Germany [32]. The assay precision is stated to be less than
8%, the mean recovery 99.9% and the detection limit better
than 0.5 ng/ml (ARCHITECT® CEA assay datasheet).
All biomarker determinations were performed blinded
to the technicians and to the study endpoint.
Statistical analysis
Rank sum tests were used for test of location and Spear-
man’s rank correlation was used as a measure for associ-
ation. Univariate and multivariate Cox regression models
were used to assess the association of total Cat X and
other clinicopathologic parameters with overall survival.
Cat X was scored by its actual value on the log scale (base 2),
which means that the hazard ratios are for a two fold
difference in the marker level. The Cox model included an
interaction term in order to test the hypothesis that the
association of Cat X was not independent of chemother-
apy received by the patient. Additionally, as in the pilot
study, the median was used as a cut-off value in univariate
analysis. CEA was dichotomized at 5 ng/ml. Model assess-
ment of the proportionality assumption and linearity was
done using Schoenfeld and martingale residuals as well as
10-fold internal cross validation [33]. The results of the
model assessment confirmed the estimates. Graphical rep-
resentations of survival probabilities were presented by
Kaplan-Meier curves grouping continuous variables by
their tertiles. P-values less than 5% were considered to be
statistically significant. Statistical analysis was carried out
using SAS (v9.2, SAS Institute, Cary, N.C., USA) and R (R
Core Team (2013); R: A language and environment for
statistical computing. R statistical Computing. Vienna.
Austria. URL. http://www.R-project.org/).
The results of this project are reported in accordance
with the REMARK guidelines [34].
Results
Levels of total Cat X and CEA and association with
baseline variables
Total Cat X and CEA concentrations were measured in
sera from 264 patients with CRC. Results and descriptive
statistics are shown in Table 2. The mean level of total
Cat X in 77 control samples was 18.8 ng/ml ± 11.4 SD.
There were no significant differences in Cat X levels
between patients and controls or between disease stages,
cancer localisation and gender.
Also, Spearman’s rank correlation between total Cat X
concentrations, age and CEA showed no correlation
(r = 0.08, p = 0.22; r = 0.02, p = 0.73). Median CEA was
3.7 ng/ml (range: 0.5-5046 ng/ml).
Table 2 Descriptive statistics for total Cat X serum concentrations
Median Mean SD Minimum Lower Quartile Upper Quartile Maximum
(ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml)
All samples 23.2 23.4 6.4 8.7 19.1 27.3 47.1
Stagea p = 0.76
I 23.4 24.7 7.4 12.6 20.3 28.5 44.5
II 23.4 22.9 5.6 10.9 18.6 26.6 35.4
III 22.4 22.8 6.4 8.7 19.1 27.5 38.1
IV 22.9 23.5 6.6 10.4 18.5 27.4 47.1
Cancer localisation p = 0.36
Left-sided colon cancer 23.3 24.2 6.0 12.3 20.1 27.8 40.0
Right-sided colon cancer 22.9 22.5 6.5 8.7 16.6 27.3 38.1
Rectal cancer 23.0 23.3 6.6 9.5 18.7 26.3 47.1
Gender p = 0.49
Female 23.3 23.9 6.2 11.8 19.2 27.4 44.5
Male 23.1 23.1 6.4 8.7 18.9 26.9 47.1
a17 patients were not staged.
Values of total serum Cat X for all samples, distributed by stage, cancer localisation and by gender.
Table 3 Multivariate analysis of total Cat X concentration
and other potential factors for overall survival of 178
patients in stages I-III





Age (per 10 years) 1.58 1.24-2.02 0.0003
Stage
I 1.0
II 1.23 0.58-2.62 0.01
III 2.74 1.27-5.92
Localisation
Right-sided colon cancer 1.00
Left-sided colon cancer 1.18 0.61-2.28 0.79
Rectal Cancer 0.99 0.48-2.05
CEA (≥ 5 ng/ml vs. < 5 ng/ml)
No adjuvant chemotherapy 1.99 1.14-3.50 0.026
Adjuvant chemotherapy 0.42 0.13-1.39 0.60
Cat X (2-fold difference in HR)
No adjuvant chemotherapy 3.13 1.37-7.18 0.003
Adjuvant chemotherapy 0.51 0.20-1.33 0.88
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In the univariate and multivariate Cox regression model,
total Cat X was scored as a continuous variable on the
log scale using base 2, which means that hazard ratios
(HR) are for two fold differences. The median time from
inclusion to end of study was 4.8 years (3.9-6.0).
Univariate analysis of Cat X, scored by its log trans-
formed value in the entire set, showed no significant dif-
ferences in overall survival (HR = 1.26; 95% CI: 0.82-1.92;
p = 0.29), although high total Cat X levels were associated
with poor survival. As the pilot study demonstrated a sig-
nificant association between Cat X and overall survival,
we additionally analysed the current study using the me-
dian as a threshold, as in the pilot study. Again, no signifi-
cant difference was demonstrated (HR = 1.33; 95% CI:
0.95-1.86, p = 0.10). However, when patients in stages I-III
were analysed in this way, the difference was significant
(HR 1.69; 95% CI: 1.03-2.75; p = 0.03). Pre-specified multi-
variate analysis of time to death from all causes for pa-
tients in stages I-III, including the covariates gender, age
(per 10 years), stage, tumour localisation, adjuvant chemo-
therapy, levels of CEA and total Cat X and interactions
terms between chemotherapy and the biomarkers identi-
fied a subgroup of patients with a significant association
with the outcome of the disease, as shown in Table 3.
The estimated HR in multivariate analysis for total Cat X
was 3.13 (95% CI: 1.37-7.18) for patients who did not re-
ceive chemotherapy and 0.51 (95% CI: 0.20-1.33) for those
who received chemotherapy (interaction term p = 0.016).
The latter means that patients who did not receive chemo-
therapy and had high total Cat X serum levels, had a
significantly shorter survival (p = 0.003) comparable to that
of the whole group of patients who had not undergonechemotherapy. A weaker, but still significant, association
with survival within the same group of patients was also
observed for CEA (p = 0.026). However, interaction between
Cat X and CEA for this group of patients not receiving
chemotherapy could not be demonstrated (p = 0.73), sug-
gesting that the two markers are additive (i.e. not synergis-
tic). The generalized concordance index was 0.75 (standard
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ation in this model.
Within the group of patients who received therapy there
was no significant difference in overall survival between
patients with low and high total Cat X. These results suggest
the potential of total Cat X to predict the response to
chemotherapy. Kaplan-Meier curves provide a similar result
for patients with stages I-III, who did not receive chemo-
therapy (Figure 1A). Patients with total Cat X levels in the
third tertile exhibited a significantly shorter overall survival
than those from the first and second tertiles (p = 0.01).
When Kaplan-Meier estimates of survival are stratified to
stage III, again patients who did not receive chemotherapy
with Cat X in the third tertile showed significantly shorter
overall survival than those with low Cat X, whereas stage III
patients who received chemotherapy exhibited no significantFigure 1 Overall survival curves according to the total Cat X
values in serum from patients with CRC. The number of patients
at risk at 0, 24 and 48 months is shown below the axis for each
stratum and the number of deaths (events) is shown to the left. The
difference between the strata was tested using the log rank test.
(A) Kaplan-Meier estimates of survival for patients with stages I-III
who did not receive chemotherapy. Cat X has been grouped using
tertiles (denoted 0, 1, 2) (B) Kaplan-Meier estimates of survival for
patients with stage III who, 0: did not receive chemotherapy and
had low Cat X, 1: did not receive chemotherapy and had high Cat X,
2: received chemotherapy and had low Cat X, 3: received chemotherapy
and had high Cat X.difference with regard to Cat X levels (Figure 1B). Inclusion
of specific first line chemotherapies in multivariate analyses
did not demonstrate significant interactions between specific
therapy and Cat X (data not shown). Therapies involving
5-Fluorouracil (5-FU), Oxaliplatin and Capecitabine were
tested in stages I-III and stage IV. However this study is not
designed or powered to address this question.
No significant effect of Cat X on survival could be dem-
onstrated for stage IV, nor for univariate (HR = 1.02; 95%
CI: 0.54-1.93; p = 0.95) or multivariate (HR = 0.68; 95% CI:
0.34-1.39; p = 0.29) analysis. Including patients not staged,
a similar result was found (data not shown). 33 (48%)
patients with stage IV received palliative chemotherapy
but no significant interaction between total Cat X and
chemotherapy could be demonstrated (p = 0.21).
Discussion
Colorectal cancer is the second leading cause of cancer-
related death in Europe and the US. About half of the
patients develop recurrent disease within 3 to 5 years of
resection of the primary tumour, and they are candidates
for systemic chemotherapy. The availability of validated
biological markers for selection of chemotherapy and pre-
diction of treatment efficacy, together with monitoring,
may increase patient survival. In this study we identified
serum Cat X as a potential tumour marker in CRC, based
on the demonstrated correlation of its high levels with
shorter patient overall survival and the association with
the adjuvant chemotherapy.
In our previous (pilot) study on 77 CRC patients [30]
we found that levels of total Cat X in sera from patients
with CRC were not significantly higher than those in
groups of healthy persons, patients with adenomas or
patients with non-neoplastic findings, all matched with
CRC patients for age and gender. The mean level of total
Cat X, determined in sera from the 264 CRC patients
included in this confirmation study, also does not differ
statistically from that in healthy persons (mean 23.4 ng/
mL ± 6.4 SD vs. 18.8 ng/ml ± 11.4 SD, p > 0.05). As in
the pilot study, there is no significant association with
patient age or gender, tumour stage or location and
CEA. In a univariate Cox regression model, the levels of
total Cat X evaluated in this study did not confirm the
significant relation to overall survival found in the pilot
study [30], although the higher levels were associated
with poor survival. When, as in the pilot study, the
median was used as a cut off value, a similar result was
obtained for the entire set of patients whereas, for patients
with local resectable disease (stages I-III), the relation to
overall survival was significant. In contrast, for patients
with metastatic disease (stage IV), there was no relation
between Cat X and overall survival. In multivariate ana-
lysis, including patients with stages I-III, a strong associ-
ation (HR = 3.13) between high total Cat X levels and
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tients who did not receive adjuvant chemotherapy whereas,
within the group of patients who received chemotherapy,
there was no association between total Cat X and survival
(HR = 0.51). Patient age, stage and CEA also contributed to
the prognosis in multivariate analysis, whereas gender and
location were not significant. The significant interaction
between Cat X and adjuvant chemotherapy suggests its
possible predictive value, since the data suggest that pa-
tients with high levels of Cat X benefit from the therapy.
Several mechanisms have been suggested that could link
higher activity and/or concentration of Cat X with the pro-
gression of malignant disease. Cat X can be present in sera
from healthy persons due to constitutive secretion by leu-
kocytes during normal physiological immune cell activa-
tion and turnover [18]. Increased secretion of pro-Cat X
could reflect the overexpression of Cat X in tumour and
tumour associated immune cells, as observed in several
cancer types. Secreted pro-Cat X most probably remains
in the extracellular space, however, it can be activated by
membrane bound cathepsin L [35] or surface heparan
sulphate proteoglycans [13]. The activation by cathepsin L
can also take place in endosomal/lysosomal vesicles during
their translocation toward the plasma membrane [15,35].
Pro-Cat X can modulate cell adhesion and motility
through interaction of its pro-region with heparan
sulphate proteoglycans [13] and integrin receptors [36-38],
while active Cat X can regulate cell functions through
cleavage of C-terminal amino acids of chemokine CXCL-
12 [26], beta-2 chain of integrin receptors [36], gamma-
enolase (neuronal specific enolase - NSE) [16] and profilin
[39,40]. Therefore, both forms could promote tumour
progression processes, resulting in enhanced adhesion
and migration of tumour cells, induced epithelial-
mesenchymal transition [27] and decreased cell senes-
cence [25]. Results obtained on transgenic animals further
confirm the active role of Cat X in tumour progression. It
was suggested that Cat X, not being dependent on the
degradation of extracellular matrix, a typical event for ca-
thepsin B, may compensate the malignant effects of cathep-
sin B [24,41] by changing the migration mode of tumour
cells. Only mice with excluded expression of both cathepsin
B and Cat X exhibited significantly lower tumour growth
and metastasis formation. The relation between Cat X
levels and response to therapy has not been reported, how-
ever, anticancer drugs may interfere with Cat X targets and
processes, also regulating its expression and secretion.
From previous studies it is not clear whether Cat X is
involved in early or late stages of cancer. The results by
Sevenich et al. [24], using a PymT-induced metastatic
breast cancer mouse model, showed that Cat X was
related to the initial stages of the malignant process and
less with tumour progression and metastasis. On the
other hand, Hidaka et al. showed that Cat X could beinvolved in the later stages of cancer, since amplification
of the region encoding for Cat X correlated with the meta-
static potential and tumour progression in CRC [20]. A
similar possibility was explored by Wang et al. [27], who
showed that increased Cat X expression strongly corre-
lated with advanced clinical stage, and induced metastatic
potential and shorter overall survival of patients with he-
patocellular carcinoma. Moreover, it was recently demon-
strated that, in adenocarcinoma of the pancreatic duct,
S100P-binding protein inversely regulates Cat X expres-
sion – lower levels of S100P-binding protein increased
Cat X, cell adhesion and metastatic potential of pancreatic
cancer cells [42]. Our findings are in accord with those of
a recent study on lung cancer patients by Zhang et al.,
which also shows that higher Cat X serum levels are asso-
ciated with shorter patient survival. However, lung cancer
patients had significantly higher Cat X levels than healthy
controls, which was not the case in our study [43]. Our
combined results support the studies revealing the associ-
ation of Cat X expression with the progression of CRC,
since they provide the correlation of high levels of Cat X
with shorter overall survival of CRC patients.
Conclusions
Our study confirms the previous results relating higher
Cat X levels to progression of cancer and shorter overall
survival of CRC patients. Although total Cat X serum
levels did not differ between the entire group of patients
and controls, a significant difference was found in the
group of patients who did not receive adjuvant chemo-
therapy: patients with high total Cat X serum levels had
significantly shorter overall survival than those with low
levels. For patients who received adjuvant chemotherapy
no difference in overall survival was observed between
those groups with low and high total Cat X. Thus, total
Cat X could be useful as a predictive, blood-based tumour
marker that may allow selection of patients who could
benefit from adjuvant chemotherapy. However, the results
must be confirmed in a prospective clinical study.
Additional files
Additional file 1: Figure S1. Calibration curve for human total Cat X.
Additional file 2: Figure S2. Linearity of the total Cat X ELISA. Dilution
curves of four sera from CRC patients. Sera were serially diluted (1/2, 1/4,
1/8, 1/16).
Additional file 3: Figure S3. Analytical recovery. Observed total Cat X
concentrations vs. expected total Cat X concentrations in serum samples
from patients with CRC. Three different amounts of pro-Cat X were added
to known amounts of total Cat X in two serum samples.
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